Cost-utility analysis of Social Stories™ for children with autism spectrum disorder in mainstream primary schools: results from a randomised controlled trial.

Autism spectrum disorders Social Stories child and adolescent cost-effectiveness quality-adjusted life-years

Journal

BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931

Informations de publication

Date de publication:
03 Jun 2024
Historique:
medline: 3 6 2024
pubmed: 3 6 2024
entrez: 3 6 2024
Statut: epublish

Résumé

One in 57 children are diagnosed with autism in the UK, and the estimated cost for supporting these children in education is substantial. Social Stories™ is a promising and widely used intervention for supporting children with autism in schools and families. It is believed that Social Stories™ can provide meaningful social information to children that can improve social understanding and may reduce anxiety. However, no economic evaluation of Social Stories has been conducted. To assess the cost-effectiveness of Social Stories through Autism Spectrum Social Stories in Schools Trial 2, a multi-site, pragmatic, cluster-randomised controlled trial. Children with autism who were aged 4-11 years were recruited and randomised ( Social Stories is likely to result in a small cost savings (-£191 per child, 95% CI -767.7 to 337.7) and maintain similar QALY improvements compared with usual care. The probability of Social Stories being a preferred option is 75% if society is willing to pay £20 000 per QALY gained. The sensitivity analysis results aligned with the main study outcomes. Compared with usual care, Social Stories did not lead to an increase in costs and maintained similar QALY improvements for primary-aged children with autism.

Sections du résumé

BACKGROUND BACKGROUND
One in 57 children are diagnosed with autism in the UK, and the estimated cost for supporting these children in education is substantial. Social Stories™ is a promising and widely used intervention for supporting children with autism in schools and families. It is believed that Social Stories™ can provide meaningful social information to children that can improve social understanding and may reduce anxiety. However, no economic evaluation of Social Stories has been conducted.
AIMS OBJECTIVE
To assess the cost-effectiveness of Social Stories through Autism Spectrum Social Stories in Schools Trial 2, a multi-site, pragmatic, cluster-randomised controlled trial.
METHOD METHODS
Children with autism who were aged 4-11 years were recruited and randomised (
RESULTS RESULTS
Social Stories is likely to result in a small cost savings (-£191 per child, 95% CI -767.7 to 337.7) and maintain similar QALY improvements compared with usual care. The probability of Social Stories being a preferred option is 75% if society is willing to pay £20 000 per QALY gained. The sensitivity analysis results aligned with the main study outcomes.
CONCLUSIONS CONCLUSIONS
Compared with usual care, Social Stories did not lead to an increase in costs and maintained similar QALY improvements for primary-aged children with autism.

Identifiants

DOI: 10.1192/bjo.2024.47 PMID: 38826027
pubmed: 38826027
doi: 10.1192/bjo.2024.47
pii: S2056472424000474
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e123

Auteurs

Han-I Wang (HI)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.
ORCID: 0000-0002-3521-993X

Kerry Bell (K)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.

Jane Blackwell (J)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.

Charlie Welch (C)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.
ORCID: 0000-0002-2421-5538

Laura Mandefield (L)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.

Judith Watson (J)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.

Emma Standley (E)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.

Dean McMillan (D)

Department of Health Sciences, University of York, UK; and Hull York Medical School, University of York, UK.

Simon Gilbody (S)

Department of Health Sciences, University of York, UK; and Hull York Medical School, University of York, UK.
ORCID: 0000-0002-8236-6983

Barry Wright (B)

Department of Health Sciences, University of York, UK; Hull York Medical School, University of York, UK; and Child Oriented Mental Health Intervention Centre (COMIC), Leeds and York Partnership NHS Foundation Trust, York, UK.

Catherine Hewitt (C)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.

Steve Parrott (S)

Department of Health Sciences, University of York, UK; and York Trial Unit, Department of Health Sciences, University of York, UK.

Classifications MeSH